Important Safety Information
Indications

INDICATIONS

  • IDACIO is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. IDACIO can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).

  • IDACIO is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. IDACIO can be used alone or in combination with methotrexate.

  • IDACIO is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. IDACIO can be used alone or in combination with non-biologic DMARDs.

  • IDACIO is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.

  • IDACIO is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.

  • IDACIO is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. IDACIO should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

  • IDACIO is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.
    Limitations of Use
    The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers.

IMPORTANT SAFETY INFORMATION

SERIOUS INFECTIONS

Patients treated with IDACIO® (adalimumab-aacf) are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue IDACIO® if a patient develops a serious infection or sepsis.

Reported infections include:

  • Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before IDACIO® use and during therapy. Initiate treatment for latent TB prior to IDACIO® use.

  • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.

  • Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.

Carefully consider the risks and benefits of treatment with IDACIO® prior to initiating therapy in patients: 1. with chronic or recurrent infection, 2. who have been exposed to TB, 3. with a history of opportunistic infection, 4. who resided in or traveled in regions where mycoses are endemic, 5. with underlying conditions that may predispose them to infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with IDACIO®, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

Treatment with IDACIO® should not be initiated in patients with an active infection, including localized infections.

Patients 65 years of age and older, patients with co-morbid conditions and/or patients taking concomitant immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk of infection.

Discontinue IDACIO® if a patient develops a serious infection or sepsis. For a patient who develops a new infection during treatment with IDACIO®, closely monitor them, perform a prompt and complete diagnostic workup appropriate for an immunocompromised patient, and initiate appropriate antimicrobial therapy.

Drug interactions with biologic products: A higher rate of serious infections has been observed in RA patients treated with rituximab who received subsequent treatment with a TNF blocker. An increased risk of serious infections has been seen with the combination of TNF blockers with anakinra or abatacept, with no demonstrated added benefit in patients with RA. Concomitant administration of adalimumab products with other biologic DMARDs (e.g., anakinra or abatacept) or other TNF blockers is not recommended based on the possible increased risk for infections and other potential pharmacological interactions.

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including adalimumab products. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants

  • Consider the risks and benefits of TNF-blocker treatment prior to initiating or continuing therapy in a patient with known malignancy.

  • In clinical trials of some TNF-blockers, including adalimumab products, more cases of malignancies were observed among TNF-blocker-treated patients compared to control patients.

  • Non-melanoma skin cancer (NMSC) was reported during clinical trials for adalimumab-treated patients. Examine all patients, particularly those with a history of prolonged immunosuppressant or PUVA therapy, for the presence of NMSC prior to and during treatment with IDACIO®.

  • In adalimumab clinical trials, there was an approximate 3-fold higher rate of lymphoma than expected in the general U.S. population. Patients with chronic inflammatory diseases, particularly those with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at higher risk of lymphoma than the general population, even in the absence of TNF blockers.

  • Postmarketing cases of acute and chronic leukemia were reported with TNF blocker use. Approximately half of the postmarketing cases of malignancies in children, adolescents, and young adults receiving TNF blockers were lymphomas; other cases included rare malignancies associated with immunosuppression and malignancies not usually observed in children and adolescents.

HYPERSENSITIVITY

Anaphylaxis and angioneurotic edema have been reported following administration of adalimumab products. If an anaphylactic or other serious allergic reaction occurs, immediately discontinue administration of IDACIO® and institute appropriate therapy. In clinical trials of adalimumab, hypersensitivity reactions (e.g., rash, anaphylactoid reaction, fixed drug reaction, non-specified drug reaction, urticaria) have been observed.

HEPATITIS B VIRUS REACTIVATION

Use of TNF blockers, including IDACIO®, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. In some instances, HBV reactivation occurring in conjunction with TNF blocker therapy has been fatal.

Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating TNF blocker therapy.

Exercise caution in prescribing TNF blockers for patients identified as carriers of HBV.

In patients who develop HBV reactivation, stop IDACIO® and initiate effective anti-viral therapy with appropriate supportive treatment. The safety of resuming TNF blocker therapy after HBV reactivation is controlled is not known. Therefore, exercise caution when considering resumption of IDACIO® therapy in this situation and monitor patients closely.

NEUROLOGICAL REACTIONS

Use of TNF blocking agents, including adalimumab products, has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease, including multiple sclerosis (MS) and optic neuritis, and peripheral demyelinating disease, including Guillain-Barré syndrome.

Exercise caution in considering the use of IDACIO® in patients with pre-existing or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of IDACIO® should be considered if any of these disorders develop.

HEMATOLOGICAL REACTIONS

Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia has been infrequently reported with adalimumab products.

Consider stopping IDACIO® if significant hematologic abnormalities occur.

CONGESTIVE HEART FAILURE

Worsening or new onset congestive heart failure (CHF) may occur; exercise caution and monitor carefully.

AUTOIMMUNITY

Treatment with adalimumab products may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop.

IMMUNIZATIONS

Patients on IDACIO® should not receive live vaccines. Pediatric patients, if possible, should be brought up to date with all immunizations before initiating IDACIO® therapy. The safety of administering live or live-attenuated vaccines in infants exposed to adalimumab products in utero is unknown. Risks and benefits should be considered prior to vaccinating (live or live-attenuated) exposed infants.

ADVERSE REACTIONS

The most common adverse reactions in adalimumab clinical trials (>10%) were: infections (e.g. upper respiratory, sinusitis), injection site reactions, headache and rash.

INDICATIONS

  • Rheumatoid Arthritis (RA): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA.

  • Juvenile Idiopathic Arthritis (JIA): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older.

  • Psoriatic Arthritis (PsA): reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA.

  • Ankylosing Spondylitis (AS): reducing signs and symptoms in adult patients with active AS.

  • Crohn’s Disease (CD): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.

  • Ulcerative Colitis (UC): treatment of moderately to severely active ulcerative colitis in adult patients.

    Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.

  • Plaque Psoriasis (PsO): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.

Please see full Prescribing Information, including boxed WARNING, for IDACIO® (adalimumab-aacf).

Safety & Evidence

An adalimumab biosimilar at the core of your needs

IDACIO® (adalimumab-aacf) is FDA-approved based on proven similarity to Humira® (adalimumab) in terms of PK/PD, efficacy, safety, and immunogenicity.1-5 Analyzed in two phase III clinical studies, IDACIO meets rigorous FDA requirements for biosimilarity based on its totality of evidence.1-4

PK=pharmacokinetics; PD=pharmacodynamics

Yellow-circled illustration of a check mark inside a shield
Safety
Yellow-circled illustration of a DNA strand
PK/PD
Yellow-circled illustration of an asterisk symbolizing “efficacy”
Efficacy
Yellow-circled illustration of a microscope
Immunogenicity

NO CLINICALLY MEANINGFUL DIFFERENCES

Biosimilarity means the biologic is highly similar to, and has no clinically meaningful differences from, the existing FDA-approved reference product.6

Table outlining steps to FDA approval for biosimilars
FDA approval process

AN FDA-APPROVED ADALIMUMAB BIOSIMILAR AT THE CORE OF YOUR NEEDS

AURIEL-RA Study

IDACIO (adalimumab-aacf) was shown to have no clinically meaningful differences from Humira (adalimumab) in terms of safety3

Primary endpoint: patients with moderately-to-severely active RA* who experienced AESI* by Week 52 were similar across treatment arms4

Bar graph showing the Primary Endpoint of the AURIEL-RA study
Bar graph showing the Primary Endpoint of the AURIEL-RA study

*RA=rheumatoid arthritis; AESI=adverse events of special interest (predefined as hypersensitivity); NS=not statistically significant; CI=confidence interval.

IDACIO (adalimumab-aacf) was shown to have no clinically meaningful differences from Humira (adalimumab) in terms of efficacy3

Secondary endpoint: IDACIO demonstrated comparable ACR20*, 50*, and 70* response rates to Humira, sustained over 52 weeks

Line graph showing Secondary Endpoint of the AURIEL-RA study
Line graph showing Secondary Endpoint of the AURIEL-RA study

*RA=rheumatoid arthritis; CI=confidence interval; NS=not statistically significant. ACR20 (50,70)= ≥20% (50%, 70%) improvement in American College of Rheumatology core set measurements from baseline.

IDACIO (adalimumab-aacf) was shown to have no clinically meaningful differences from Humira (adalimumab) in terms of safety3

Safety: IDACIO demonstrated comparable rates of treatment-emergent adverse events (TEAEs) to Humira, sustained up to Week 52

Table showing IDACIO's AURIEL-RA Study Safety & Immunogenicity
Table showing IDACIO's AURIEL-RA Study Safety & Immunogenicity

Patients receiving IDACIO had similar rates of positive NAb* and ADA* results compared with patients receiving Humira (NAb: 39.9% and 39.3%; ADA: 80.4% and 71.7%, respectively).4

*RA=rheumatoid arthritis; NAb=neutralizing antibody; ADA=anti-drug antibody.

IDACIO AURIEL-RA study design

In a phase III, multicenter, randomized, double-blind, parallel group study, the safety, efficacy, and immunogenicity of IDACIO was compared to Humira in patients with moderately-to-severely active RA4

Line graph outlining of IDACIO AURIEL-RA study design
Line graph outlining of IDACIO AURIEL-RA study design

RA=rheumatoid arthritis; EOW=every other week.

AURIEL-PsO Study

IDACIO (adalimumab-aacf) was shown to have no clinically meaningful differences from Humira (adalimumab) in terms of efficacy3

Primary endpoint: PASI 75* response rate at Week 16 was similar across treatment arms in moderate-to-severe PsO* patientsb

Bar graph showing the Primary Endpoint of the AURIEL-PsO study
Bar graph showing the Primary Endpoint of the AURIEL-PsO study

*PsO=plaque psoriasis; PASI=psoriasis area and severity index; CI=confidence interval.

bPer-protocol population included all patients who completed the 16-week study without major protocol violations.

IDACIO (adalimumab-aacf) was shown to have no clinically meaningful differences from Humira (adalimumab) in terms of efficacy3

Secondary endpoint: similar PASI 50/75/90/100* response rates up to Week 52c in moderate-to-severe PsO* patients

Line graph showing Secondary Endpoint of the AURIEL-PsO study
Line graph showing Secondary Endpoint of the AURIEL-PsO study

*PsO=plaque psoriasis; PASI=psoriasis area and severity index; NS=not statistically significant.

cPer-protocol population included all patients who completed the 16-week study without major protocol violations.

dPatient numbers at Week 52.

IDACIO (adalimumab-aacf) was shown to have no clinically meaningful differences from Humira (adalimumab) in terms of safety3

There were no clinically meaningful differences in treatment-emergent adverse events between treatment arms in patients with moderate-to-severe PsO3,7

Table showing IDACIO's AURIEL-PsO Study Safety & Immunogenicity data
Table showing IDACIO's AURIEL-PsO Study Safety & Immunogenicity data

Patients receiving IDACIO had similar rates of positive NAb and ADA results compared with patients receiving Humira (NAb: 41.1% and 42.3%; ADA: 88.1% and 88.4%, respectively).7

PsO=plaque psoriasis; TEAE=treatment-emergent adverse events; NAb=neutralizing antibody; ADA=anti-drug antibody.

eSerious infection, latent tuberculosis infection, or active tuberculosis infection.

fIncludes the following preferred terms: injection site bruising, injection site erythema, injection site hematoma, injection site hemorrhage, injection site induration, injection site edema, injection site pain, injection site pruritus, injection site rash, injection site swelling.

gIncludes the following preferred terms: injection site rash, anaphylactic shock, drug hypersensitivity, rash pustular, rhinitis allergic, dermatitis, dermatitis allergic, dermatitis contact, eczema, erythema multiforme, hypersensitivity vasculitis, idiopathic urticaria, rash, urticaria.

IDACIO AURIEL-PsO study design

In a phase III, multicenter, randomized, double-blind, parallel group study, the safety, efficacy, and immunogenicity of IDACIO was compared to Humira in patients with moderately-to-severely active PsO3

Line graph outlining the IDACIO AURIEL-PsO study design
Line graph outlining the IDACIO AURIEL-PsO study design

PsO=plaque psoriasis; EOW=every other week.

*Last administration of trial treatment at Week 50, efficacy and immunogenicity last evaluated at Week 52, and safety evaluated at Week 54.

AURIEL-PsO Study: Switch Data

IDACIO (adalimumab-aacf) was shown to have no clinically meaningful differences from Humira (adalimumab) in switch patients3,7

EFFICACY RETAINED IN SWITCHING ARM

Similar PASI 50/75/90/100* response rates at Week 52 in moderate-to-severe PsO* patients7,h

Bar graph showing similarity of IDACIO's efficacy to Humira in transitioning patients in the AURIEL-PsO study
Bar graph showing similarity of IDACIO's efficacy to Humira in switch patients in the AURIEL-PsO study

*PsO=plaque psoriasis; PASI=psoriasis area and severity index; NS=not statistically significant.

hPer-protocol population included all patients who completed the 16-week study without major protocol violations.

iLast administration of trial treatment at Week 50, efficacy and immunogenicity last evaluated at Week 52 and safety at Week 54.

The safety of IDACIO (adalimumab-aacf) was demonstrated to be highly similar to Humira (adalimumab) in switch patients3

IDACIO demonstrated comparable rates of treatment-emergent adverse events (TEAEs) to Humira between treatment arms, including the switching arm, sustained over 66 weeks.3

Table showing IDACIO's AURIEL-PsO Switch Safety & Immunogenicity data
Table showing IDACIO's AURIEL-PsO Switch Safety & Immunogenicity data

Patients receiving IDACIO had similar rates of positive NAb* and ADA* results compared with patients receiving Humira and patients in the switch treatment arm (NAb: 63%, 61.4%, and 58.4%, respectively; ADA: 93.2%, 92.1%, and 94.1%, respectively).3

PsO=plaque psoriasis; TEAE=treatment-emergent adverse events; NAb=neutralizing antibody; ADA=anti-drug antibody.

eSerious infection, latent tuberculosis infection, or active tuberculosis infection.

fIncludes the following preferred terms: injection site bruising, injection site erythema, injection site hematoma, injection site hemorrhage, injection site induration, injection site edema, injection site pain, injection site pruritus, injection site rash, injection site swelling.

gIncludes the following preferred terms: injection site rash, anaphylactic shock, drug hypersensitivity, rash pustular, rhinitis allergic, dermatitis, dermatitis allergic, dermatitis contact, eczema, erythema multiforme, hypersensitivity vasculitis, idiopathic urticaria, rash, urticaria.

IDACIO AURIEL-PsO study design

In a phase III, multicenter, randomized, double-blind, parallel group study, the safety, efficacy, and immunogenicity of IDACIO was compared to Humira in patients with moderately-to-severely active PsO3

Line graph outlining the IDACIO AURIEL-PsO study design
Line graph outlining the IDACIO AURIEL-PsO study design

AURIEL-PsO Study

IDACIO (adalimumab-aacf) was shown to have no clinically meaningful differences from Humira (adalimumab) in terms of efficacy3

Primary endpoint: PASI 75* response rate at Week 16 was similar across treatment arms in moderate-to-severe PsO* patientsb

Bar graph showing the Primary Endpoint of the AURIEL-PsO study
Bar graph showing the Primary Endpoint of the AURIEL-PsO study

*PsO=plaque psoriasis; PASI=psoriasis area and severity index; CI=confidence interval.

bPer-protocol population included all patients who completed the 16-week study without major protocol violations.

IDACIO (adalimumab-aacf) was shown to have no clinically meaningful differences from Humira (adalimumab) in terms of efficacy3

Secondary endpoint: similar PASI 50/75/90/100* response rates up to Week 52c in moderate-to-severe PsO* patients

Line graph showing Secondary Endpoint of the AURIEL-PsO study
Line graph showing Secondary Endpoint of the AURIEL-PsO study

*PsO=plaque psoriasis; PASI=psoriasis area and severity index; NS=not statistically significant.

cPer-protocol population included all patients who completed the 16-week study without major protocol violations.

dPatient numbers at Week 52.

IDACIO (adalimumab-aacf) was shown to have no clinically meaningful differences from Humira (adalimumab) in terms of safety3

There were no clinically meaningful differences in treatment-emergent adverse events between treatment arms in patients with moderate-to-severe PsO3,7

Table showing IDACIO's AURIEL-PsO Study Safety & Immunogenicity data
Table showing IDACIO's AURIEL-PsO Study Safety & Immunogenicity data

Patients receiving IDACIO had similar rates of positive NAb* and ADA* results compared with patients receiving Humira (NAb: 41.1% and 42.3%; ADA: 88.1% and 88.4%, respectively).7

PsO=plaque psoriasis; TEAE=treatment-emergent adverse events; NAb=neutralizing antibody; ADA=anti-drug antibody.

eSerious infection, latent tuberculosis infection, or active tuberculosis infection.

fIncludes the following preferred terms: injection site bruising, injection site erythema, injection site hematoma, injection site hemorrhage, injection site induration, injection site edema, injection site pain, injection site pruritus, injection site rash, injection site swelling.

gIncludes the following preferred terms: injection site rash, anaphylactic shock, drug hypersensitivity, rash pustular, rhinitis allergic, dermatitis, dermatitis allergic, dermatitis contact, eczema, erythema multiforme, hypersensitivity vasculitis, idiopathic urticaria, rash, urticaria.

IDACIO AURIEL-PsO study design

In a phase III, multicenter, randomized, double-blind, parallel group study, the safety, efficacy, and immunogenicity of IDACIO was compared to Humira in patients with moderately-to-severe PsO3

Line graph outlining the IDACIO AURIEL-PsO study design
Line graph outlining the IDACIO AURIEL-PsO study design

*Last administration of trial treatment at Week 50, efficacy and immunogenicity last evaluated at Week 52, and safety evaluated at Week 54.

PsO=plaque psoriasis; EOW=every other week.

AURIEL-PsO Study: switch data

IDACIO (adalimumab-aacf) was shown to have no clinically meaningful differences from Humira (adalimumab) in switch patients3,7

EFFICACY RETAINED IN SWITCHING ARM

Similar PASI 50/75/90/100* response rates at Week 52 in moderate-to-severe PsO* patients3,h

Bar graph showing similarity of IDACIO's efficacy to Humira in transitioning patients in the AURIEL-PsO study
Bar graph showing similarity of IDACIO's efficacy to Humira in switch patients in the AURIEL-PsO study

*PsO=plaque psoriasis; PASI=psoriasis area and severity index; NS=not statistically significant.

hPer-protocol population included all patients who completed the 16-week study without major protocol violations.

iLast administration of trial treatment at Week 50, efficacy and immunogenicity last evaluated at Week 52 and safety at Week 54.

The safety of IDACIO (adalimumab-aacf) was demonstrated to be highly similar to Humira (adalimumab) in switch patients3

IDACIO demonstrated comparable rates of treatment-emergent adverse events (TEAEs) to Humira between treatment arms, including the switching arm, sustained over 66 weeks.3

Table showing IDACIO's AURIEL-PsO Switch Safety & Immunogenicity data
Table showing IDACIO's AURIEL-PsO Switch Safety & Immunogenicity data

Patients receiving IDACIO had similar rates of positive NAb* and ADA* results compared with patients receiving Humira and patients in the switch treatment arm (NAb: 63%, 61.4%, and 58.4%, respectively; ADA: 93.2%, 92.1%, and 94.1%, respectively).3

PsO=plaque psoriasis; TEAE=treatment-emergent adverse events; NAb=neutralizing antibody; ADA=anti-drug antibody.

eSerious infection, latent tuberculosis infection, or active tuberculosis infection.

fIncludes the following preferred terms: injection site bruising, injection site erythema, injection site hematoma, injection site hemorrhage, injection site induration, injection site edema, injection site pain, injection site pruritus, injection site rash, injection site swelling.

gIncludes the following preferred terms: injection site rash, anaphylactic shock, drug hypersensitivity, rash pustular, rhinitis allergic, dermatitis, dermatitis allergic, dermatitis contact, eczema, erythema multiforme, hypersensitivity vasculitis, idiopathic urticaria, rash, urticaria.

IDACIO AURIEL-PsO study design

In a phase III, multicenter, randomized, double-blind, parallel group study, the safety, efficacy, and immunogenicity of IDACIO was compared to Humira in patients with moderately-to-severely active PsO3

Line graph outlining the IDACIO AURIEL-PsO study design
Line graph outlining the IDACIO AURIEL-PsO study design

AURIEL-PsO Study

IDACIO (adalimumab-aacf) was shown to have no clinically meaningful differences from Humira (adalimumab) in terms of efficacy3

Primary endpoint: PASI 75* response rate at Week 16 was similar across treatment arms in moderate-to-severe PsO* patientsb

Bar graph showing the Primary Endpoint of the AURIEL-PsO study
Bar graph showing the Primary Endpoint of the AURIEL-PsO study
Bar graph showing the Primary Endpoint of the AURIEL-PsO study
Bar graph showing the Primary Endpoint of the AURIEL-PsO study

*PsO=plaque psoriasis; PASI=psoriasis area and severity index; CI=confidence interval.

bPer-protocol population included all patients who completed the 16-week study without major protocol violations.

IDACIO (adalimumab-aacf) was shown to have no clinically meaningful differences from Humira (adalimumab) in terms of efficacy3

Secondary endpoint: similar PASI 50/75/90/100* response rates up to Week 52c in moderate-to-severe PsO* patients

Line graph showing Secondary Endpoint of the AURIEL-PsO study
Line graph showing Secondary Endpoint of the AURIEL-PsO study
Line graph showing Secondary Endpoint of the AURIEL-PsO study

*PsO=plaque psoriasis; PASI=psoriasis area and severity index; NS=not statistically significant.

cPer-protocol population included all patients who completed the 16-week study without major protocol violations.

dPatient numbers at Week 52.

IDACIO (adalimumab-aacf) was shown to have no clinically meaningful differences from Humira (adalimumab) in terms of safety3

There were no clinically meaningful differences in treatment-emergent adverse events between treatment arms in patients with moderate-to-severe PsO3,7

Table showing IDACIO's AURIEL-PsO Study Safety & Immunogenicity data
Table showing IDACIO's AURIEL-PsO Study Safety & Immunogenicity data
Table showing IDACIO's AURIEL-PsO Study Safety & Immunogenicity data

Patients receiving IDACIO had similar rates of positive NAb* and ADA* results compared with patients receiving Humira (NAb: 41.1% and 42.3%; ADA: 88.1% and 88.4%, respectively).7

PsO=plaque psoriasis; TEAE=treatment-emergent adverse events; NAb=neutralizing antibody; ADA=anti-drug antibody.

eSerious infection, latent tuberculosis infection, or active tuberculosis infection.

fIncludes the following preferred terms: injection site bruising, injection site erythema, injection site hematoma, injection site hemorrhage, injection site induration, injection site edema, injection site pain, injection site pruritus, injection site rash, injection site swelling.

gIncludes the following preferred terms: injection site rash, anaphylactic shock, drug hypersensitivity, rash pustular, rhinitis allergic, dermatitis, dermatitis allergic, dermatitis contact, eczema, erythema multiforme, hypersensitivity vasculitis, idiopathic urticaria, rash, urticaria.

IDACIO AURIEL-PsO study design

In a phase III, multicenter, randomized, double-blind, parallel group study, the safety, efficacy, and immunogenicity of IDACIO was compared to Humira in patients with moderately-to-severely active PsO3

Line graph outlining the IDACIO AURIEL-PsO study design
Line graph outlining the IDACIO AURIEL-PsO study design
Line graph outlining the IDACIO AURIEL-PsO study design

PsO=plaque psoriasis; EOW=every other week.

*Last administration of trial treatment at Week 50, efficacy and immunogenicity last evaluated at Week 52, and safety evaluated at Week 54.

AURIEL-PsO Study: switch data

IDACIO (adalimumab-aacf) was shown to have no clinically meaningful differences from Humira (adalimumab) in switch patients3,7

EFFICACY RETAINED IN SWITCHING ARM

Similar PASI 50/75/90/100* response rates at Week 52 in moderate-to-severe PsO* patients3,h

Bar graph showing similarity of IDACIO's efficacy to Humira in transitioning patients in the AURIEL-PsO study
Bar graph showing similarity of IDACIO's efficacy to Humira in switch patients in the AURIEL-PsO study

*PsO=plaque psoriasis; PASI=psoriasis area and severity index; NS=not statistically significant.

hPer-protocol population included all patients who completed the 16-week study without major protocol violations.

iLast administration of trial treatment at Week 50, efficacy and immunogenicity last evaluated at Week 52 and safety at Week 54.

The safety of IDACIO (adalimumab-aacf) was demonstrated to be highly similar to Humira (adalimumab) in switch patients3

IDACIO demonstrated comparable rates of treatment-emergent adverse events (TEAEs) to Humira between treatment arms, including the switching arm, sustained over 66 weeks.3

Table showing IDACIO's AURIEL-PsO Switch Safety & Immunogenicity data
Table showing IDACIO's AURIEL-PsO Switch Safety & Immunogenicity data

Patients receiving IDACIO had similar rates of positive NAb* and ADA* results compared with patients receiving Humira and patients in the switch treatment arm (NAb: 63%, 61.4%, and 58.4%, respectively; ADA: 93.2%, 92.1%, and 94.1%, respectively).3

PsO=plaque psoriasis; TEAE=treatment-emergent adverse events; NAb=neutralizing antibody; ADA=anti-drug antibody.

eSerious infection, latent tuberculosis infection, or active tuberculosis infection.

fIncludes the following preferred terms: injection site bruising, injection site erythema, injection site hematoma, injection site hemorrhage, injection site induration, injection site edema, injection site pain, injection site pruritus, injection site rash, injection site swelling.

gIncludes the following preferred terms: injection site rash, anaphylactic shock, drug hypersensitivity, rash pustular, rhinitis allergic, dermatitis, dermatitis allergic, dermatitis contact, eczema, erythema multiforme, hypersensitivity vasculitis, idiopathic urticaria, rash, urticaria.

IDACIO AURIEL-PsO study design

In a phase III, multicenter, randomized, double-blind, parallel group study, the safety, efficacy, and immunogenicity of IDACIO was compared to Humira in patients with moderately-to-severely active PsO3

Line graph outlining the IDACIO AURIEL-PsO study design
Line graph outlining the IDACIO AURIEL-PsO study design
Line graph outlining the IDACIO AURIEL-PsO study design

TRANSITIONING SHOULD BE EASY

Onboarding or transitioning your patients? A biosimilar at the core of your needs can provide proven clinical similarity, updated features,1 and a reliable supply from a trusted manufacturer.

Meet your Immunology Sales Specialist

Have questions about IDACIO? Your Immunology Sales Specialist is available to help—and to provide support as you begin transitioning and treating your patients.

Connect with a specialist

Dosing & Administration

When transitioning to IDACIO, your patients can keep the same subcutaneous route of administration as Humira (adalimumab).1,8 The treatment provides patients two citrate-free administration routes and offers flexibility with room-temperature storage of up to 28 days.1

See Dosing & Administration

INDICATIONS

  • IDACIO is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. IDACIO can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).

  • IDACIO is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. IDACIO can be used alone or in combination with methotrexate.

  • IDACIO is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. IDACIO can be used alone or in combination with non-biologic DMARDs.

  • IDACIO is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.

  • IDACIO is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.

  • IDACIO is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. IDACIO should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

  • IDACIO is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.
    Limitations of Use
    The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers.

IMPORTANT SAFETY INFORMATION

SERIOUS INFECTIONS

Patients treated with IDACIO® (adalimumab-aacf) are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue IDACIO® if a patient develops a serious infection or sepsis.

Reported infections include:

  • Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before IDACIO® use and during therapy. Initiate treatment for latent TB prior to IDACIO® use.

  • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.

  • Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.

Carefully consider the risks and benefits of treatment with IDACIO® prior to initiating therapy in patients: 1. with chronic or recurrent infection, 2. who have been exposed to TB, 3. with a history of opportunistic infection, 4. who resided in or traveled in regions where mycoses are endemic, 5. with underlying conditions that may predispose them to infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with IDACIO®, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

Treatment with IDACIO® should not be initiated in patients with an active infection, including localized infections.

Patients 65 years of age and older, patients with co-morbid conditions and/or patients taking concomitant immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk of infection.

Discontinue IDACIO® if a patient develops a serious infection or sepsis. For a patient who develops a new infection during treatment with IDACIO®, closely monitor them, perform a prompt and complete diagnostic workup appropriate for an immunocompromised patient, and initiate appropriate antimicrobial therapy.

Drug interactions with biologic products: A higher rate of serious infections has been observed in RA patients treated with rituximab who received subsequent treatment with a TNF blocker. An increased risk of serious infections has been seen with the combination of TNF blockers with anakinra or abatacept, with no demonstrated added benefit in patients with RA. Concomitant administration of adalimumab products with other biologic DMARDs (e.g., anakinra or abatacept) or other TNF blockers is not recommended based on the possible increased risk for infections and other potential pharmacological interactions.

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including adalimumab products. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants

  • Consider the risks and benefits of TNF-blocker treatment prior to initiating or continuing therapy in a patient with known malignancy.

  • In clinical trials of some TNF-blockers, including adalimumab products, more cases of malignancies were observed among TNF-blocker-treated patients compared to control patients.

  • Non-melanoma skin cancer (NMSC) was reported during clinical trials for adalimumab-treated patients. Examine all patients, particularly those with a history of prolonged immunosuppressant or PUVA therapy, for the presence of NMSC prior to and during treatment with IDACIO®.

  • In adalimumab clinical trials, there was an approximate 3-fold higher rate of lymphoma than expected in the general U.S. population. Patients with chronic inflammatory diseases, particularly those with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at higher risk of lymphoma than the general population, even in the absence of TNF blockers.

  • Postmarketing cases of acute and chronic leukemia were reported with TNF blocker use. Approximately half of the postmarketing cases of malignancies in children, adolescents, and young adults receiving TNF blockers were lymphomas; other cases included rare malignancies associated with immunosuppression and malignancies not usually observed in children and adolescents.

HYPERSENSITIVITY

Anaphylaxis and angioneurotic edema have been reported following administration of adalimumab products. If an anaphylactic or other serious allergic reaction occurs, immediately discontinue administration of IDACIO® and institute appropriate therapy. In clinical trials of adalimumab, hypersensitivity reactions (e.g., rash, anaphylactoid reaction, fixed drug reaction, non-specified drug reaction, urticaria) have been observed.

HEPATITIS B VIRUS REACTIVATION

Use of TNF blockers, including IDACIO®, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. In some instances, HBV reactivation occurring in conjunction with TNF blocker therapy has been fatal.

Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating TNF blocker therapy.

Exercise caution in prescribing TNF blockers for patients identified as carriers of HBV.

In patients who develop HBV reactivation, stop IDACIO® and initiate effective anti-viral therapy with appropriate supportive treatment. The safety of resuming TNF blocker therapy after HBV reactivation is controlled is not known. Therefore, exercise caution when considering resumption of IDACIO® therapy in this situation and monitor patients closely.

NEUROLOGICAL REACTIONS

Use of TNF blocking agents, including adalimumab products, has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease, including multiple sclerosis (MS) and optic neuritis, and peripheral demyelinating disease, including Guillain-Barré syndrome.

Exercise caution in considering the use of IDACIO® in patients with pre-existing or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of IDACIO® should be considered if any of these disorders develop.

HEMATOLOGICAL REACTIONS

Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia has been infrequently reported with adalimumab products.

Consider stopping IDACIO® if significant hematologic abnormalities occur.

CONGESTIVE HEART FAILURE

Worsening or new onset congestive heart failure (CHF) may occur; exercise caution and monitor carefully.

AUTOIMMUNITY

Treatment with adalimumab products may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop.

IMMUNIZATIONS

Patients on IDACIO® should not receive live vaccines. Pediatric patients, if possible, should be brought up to date with all immunizations before initiating IDACIO® therapy. The safety of administering live or live-attenuated vaccines in infants exposed to adalimumab products in utero is unknown. Risks and benefits should be considered prior to vaccinating (live or live-attenuated) exposed infants.

ADVERSE REACTIONS

The most common adverse reactions in adalimumab clinical trials (>10%) were: infections (e.g. upper respiratory, sinusitis), injection site reactions, headache and rash.

INDICATIONS

  • Rheumatoid Arthritis (RA): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA.

  • Juvenile Idiopathic Arthritis (JIA): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older.

  • Psoriatic Arthritis (PsA): reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA.

  • Ankylosing Spondylitis (AS): reducing signs and symptoms in adult patients with active AS.

  • Crohn’s Disease (CD): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.

  • Ulcerative Colitis (UC): treatment of moderately to severely active ulcerative colitis in adult patients.

    Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.

  • Plaque Psoriasis (PsO): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.

Please see full Prescribing Information, including boxed WARNING, for IDACIO® (adalimumab-aacf).

Important Safety Information
Indications

INDICATIONS

  • IDACIO is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. IDACIO can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).

  • IDACIO is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. IDACIO can be used alone or in combination with methotrexate.

  • IDACIO is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. IDACIO can be used alone or in combination with non-biologic DMARDs.

  • IDACIO is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.

  • IDACIO is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.

  • IDACIO is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. IDACIO should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

  • IDACIO is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.
    Limitations of Use
    The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers.

IMPORTANT SAFETY INFORMATION

SERIOUS INFECTIONS

Patients treated with IDACIO® (adalimumab-aacf) are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue IDACIO® if a patient develops a serious infection or sepsis.

Reported infections include:

  • Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before IDACIO® use and during therapy. Initiate treatment for latent TB prior to IDACIO® use.

  • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.

  • Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.

Carefully consider the risks and benefits of treatment with IDACIO® prior to initiating therapy in patients: 1. with chronic or recurrent infection, 2. who have been exposed to TB, 3. with a history of opportunistic infection, 4. who resided in or traveled in regions where mycoses are endemic, 5. with underlying conditions that may predispose them to infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with IDACIO®, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

Treatment with IDACIO® should not be initiated in patients with an active infection, including localized infections.

Patients 65 years of age and older, patients with co-morbid conditions and/or patients taking concomitant immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk of infection.

Discontinue IDACIO® if a patient develops a serious infection or sepsis. For a patient who develops a new infection during treatment with IDACIO®, closely monitor them, perform a prompt and complete diagnostic workup appropriate for an immunocompromised patient, and initiate appropriate antimicrobial therapy.

Drug interactions with biologic products: A higher rate of serious infections has been observed in RA patients treated with rituximab who received subsequent treatment with a TNF blocker. An increased risk of serious infections has been seen with the combination of TNF blockers with anakinra or abatacept, with no demonstrated added benefit in patients with RA. Concomitant administration of adalimumab products with other biologic DMARDs (e.g., anakinra or abatacept) or other TNF blockers is not recommended based on the possible increased risk for infections and other potential pharmacological interactions.

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including adalimumab products. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants

  • Consider the risks and benefits of TNF-blocker treatment prior to initiating or continuing therapy in a patient with known malignancy.

  • In clinical trials of some TNF-blockers, including adalimumab products, more cases of malignancies were observed among TNF-blocker-treated patients compared to control patients.

  • Non-melanoma skin cancer (NMSC) was reported during clinical trials for adalimumab-treated patients. Examine all patients, particularly those with a history of prolonged immunosuppressant or PUVA therapy, for the presence of NMSC prior to and during treatment with IDACIO®.

  • In adalimumab clinical trials, there was an approximate 3-fold higher rate of lymphoma than expected in the general U.S. population. Patients with chronic inflammatory diseases, particularly those with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at higher risk of lymphoma than the general population, even in the absence of TNF blockers.

  • Postmarketing cases of acute and chronic leukemia were reported with TNF blocker use. Approximately half of the postmarketing cases of malignancies in children, adolescents, and young adults receiving TNF blockers were lymphomas; other cases included rare malignancies associated with immunosuppression and malignancies not usually observed in children and adolescents.

HYPERSENSITIVITY

Anaphylaxis and angioneurotic edema have been reported following administration of adalimumab products. If an anaphylactic or other serious allergic reaction occurs, immediately discontinue administration of IDACIO® and institute appropriate therapy. In clinical trials of adalimumab, hypersensitivity reactions (e.g., rash, anaphylactoid reaction, fixed drug reaction, non-specified drug reaction, urticaria) have been observed.

HEPATITIS B VIRUS REACTIVATION

Use of TNF blockers, including IDACIO®, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. In some instances, HBV reactivation occurring in conjunction with TNF blocker therapy has been fatal.

Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating TNF blocker therapy.

Exercise caution in prescribing TNF blockers for patients identified as carriers of HBV.

In patients who develop HBV reactivation, stop IDACIO® and initiate effective anti-viral therapy with appropriate supportive treatment. The safety of resuming TNF blocker therapy after HBV reactivation is controlled is not known. Therefore, exercise caution when considering resumption of IDACIO® therapy in this situation and monitor patients closely.

NEUROLOGICAL REACTIONS

Use of TNF blocking agents, including adalimumab products, has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease, including multiple sclerosis (MS) and optic neuritis, and peripheral demyelinating disease, including Guillain-Barré syndrome.

Exercise caution in considering the use of IDACIO® in patients with pre-existing or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of IDACIO® should be considered if any of these disorders develop.

HEMATOLOGICAL REACTIONS

Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia has been infrequently reported with adalimumab products.

Consider stopping IDACIO® if significant hematologic abnormalities occur.

CONGESTIVE HEART FAILURE

Worsening or new onset congestive heart failure (CHF) may occur; exercise caution and monitor carefully.

AUTOIMMUNITY

Treatment with adalimumab products may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop.

IMMUNIZATIONS

Patients on IDACIO® should not receive live vaccines. Pediatric patients, if possible, should be brought up to date with all immunizations before initiating IDACIO® therapy. The safety of administering live or live-attenuated vaccines in infants exposed to adalimumab products in utero is unknown. Risks and benefits should be considered prior to vaccinating (live or live-attenuated) exposed infants.

ADVERSE REACTIONS

The most common adverse reactions in adalimumab clinical trials (>10%) were: infections (e.g. upper respiratory, sinusitis), injection site reactions, headache and rash.

INDICATIONS

  • Rheumatoid Arthritis (RA): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA.

  • Juvenile Idiopathic Arthritis (JIA): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older.

  • Psoriatic Arthritis (PsA): reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA.

  • Ankylosing Spondylitis (AS): reducing signs and symptoms in adult patients with active AS.

  • Crohn’s Disease (CD): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.

  • Ulcerative Colitis (UC): treatment of moderately to severely active ulcerative colitis in adult patients.

    Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.

  • Plaque Psoriasis (PsO): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.

Please see full Prescribing Information, including boxed WARNING, for IDACIO® (adalimumab-aacf).

References:

  1. IDACIO® (adalimumab-aacf) injection prescribing information. Lake Zurich, IL: Fresenius Kabi USA, LLC; 2022.
  2. US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. Published 2015. Accessed February 14, 2023. https://www.fda.gov/media/82647/download
  3. Hercogova J, Papp KA, Chyrok V, et al. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2020;182(2):316-326.
  4. Edwards CJ, Monnet J, Ullmann M, et al. Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis. Clin Rheumatol. 2019;38(12):3381-3390.
  5. Hyland E, Mant T, Vlachos P, et al. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira in healthy subjects. Br J Clin Pharmacol. 2016;82(4):983-993.
  6. US Food and Drug Administration. Biological Product Definitions. Accessed February 14, 2023. https://www.fda.gov/files/drugs/published/Biological-Product-Definitions.pdf
  7. Data on file. Fresenius Kabi.
  8. HUMIRA injection [package insert]. North Chicago, IL. AbbVie Inc.